

June 16, 2023

NIKKISO Co., Ltd. Fumiaki Kanai President & CEO MIC International 4-32-16 Ryogoku Sumida-ku, Tokyo 130-0023 JAPAN

Re: K230514

Trade/Device Name: Blood Tubing Lines for Hemodialysis AL Series (Archloop); AL-ADC-E(U)06, AL-CDC-E(U)06 Blood Tubing Lines for Hemodialysis C18 Series; C18BDD-E(U)06, C18RDC-E(U)06, C18SFD-E(U)06 Regulation Number: 21 CFR 876.5820 Regulation Name: Hemodialysis system and accessories Regulatory Class: Class II Product Code: KOC Dated: June 5, 2023 Received: June 7, 2023

Dear Fumiaki Kanai:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-

<u>information/postmarketing-safety-reporting-combination-products</u>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices

(21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <u>https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems</u>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</u>) and CDRH Learn (<u>https://www.fda.gov/training-and-continuing-education/cdrh-learn</u>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</u>) for more information or contact DICE by email (<u>DICE@fda.hhs.gov</u>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Gema Gonzalez -S

Gema Gonzalez, MS Acting Assistant Director DHT3A: Division of Renal, Gastrointestinal, Obesity and Transplant Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure

Indications for Use

510(k) Number *(if known)* K230514

Device Name BLOOD TUBING LINES FOR HEMODIALYSIS AL Series (Archloop) BLOOD TUBING LINES FOR HEMODIALYSIS C18 Series

Indications for Use (Describe)

This device is indicated for hemodialysis prescribed by physicians for adult patients with acute and chronic renal failure, treated in hospitals and dialysis clinics by qualified operators. This device is not indicated for pediatric patients. It is not for home use.

This device is made up of disposable bloodlines intended to provide extracorporeal access to a patient's blood during hemodialysis. It is the responsibility of the physician or other licensed practitioner to ensure compatibility with the available configurations.

Type of Use	(Select one	or both. a	as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov*

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

5. 510(k) Summary

5 10(1.) Marcale an	K220514		
510(k) Number	K230514		
Preparation Date	June 15 th , 2023		
Submitter	NIKKISO CO., LTD.		
	20-3, Ebisu 4-Chome, Shibuya-ku		
	Tokyo 150-6022, Japan		
Contact	Satoko Hina Overlite A severe Department		
	Quality Assurance Department		
	Medical Division		
	NIKKISO CO., LTD.		
	20-3, Ebisu 4-Chome, Shibuya-ku		
	Tokyo 150-6022, Japan Phone: +81-3-3443-3754 Fax: +81-3-3473-4965		
	Email: MedicalRA@nikkiso.co.jp		
Subject Device	Device Name: BLOOD TUBING LINES FOR HEMODIALYSIS AL Series (Archloop)		
	BLOOD TUBING LINES FOR HEMODIALYSIS C18 Series		
	Device Classification Name:Accessories, Blood Circuit, HemodialysisRegulation Number:21 CFR 876.5820		
	8		
	Regulation Description:Hemodialysis system and accessoriesDevice Class:Class II		
	Classification Product Code: KOC		
	Regulation Medical Specialty: Gastroenterology/Urology510(k) Review Panel:Gastroenterology/Urology		
Device Description			
Device Description	The BLOOD TUBING LINES FOR HEMODIALYSIS AL Series (Archloop) includes arterial and venous dialysis blood tubing.		
	 The devices are packaged together for convenient use during hemodialysis procedures. They are manufactured for application with the DBB-06 Hemodialysis Delivery System. The components of the device include tubing, drip chambers, infusion tubing, pressure monitoring lines, ports, clamps and filters which are used to pump blood, retain and capture blood debris, infuse medications or fluids, sample blood as well as monitor pressure. The devices are packaged sterile and labeled for single use only. These devices cannot be cleaned or reused. They are restricted for sale by or on the order of a physician. 		
	The BLOOD TUBING LINES FOR HEMODIALYSIS C18 Series is one part of a blood tubing lines device for hemodialysis. The devices are packaged together for convenient use during hemodialysis procedures. They are manufactured for application with the DBB-06 Hemodialysis Delivery System. The devices are packaged sterile and labeled for single use only. These devices cannot be cleaned or reused. They are restricted for sale by or on the order of a physician.		
Intended Use / Indications for Use	This device is indicated for hemodialysis prescribed by physicians for adult patients with acute and chronic renal failure, treated in hospitals and dialysis clinics by qualified operators. This device is not indicated for pediatric patients. It is not for home use.		
	This device is made up of disposable bloodlines intended to provide extracorporeal access patient's blood during hemodialysis. It is the responsibility of the physician or other licer practitioner to ensure compatibility with the available configurations.		

	510(1) N 1	1/000710		
Predicate Device	510(k) Number:	K082719		
	Device Name:	NIKKLINE BLOOD TUBING LINES WITH		
		TRANSDUCER PROTECTORS, MODELS		
		AV06A-P, AV06B-P, AV06C-P		
	Applicant:	NIKKISO CO., LTD.		
	Device Classification Name:	Accessories, Blood Circuit, Hemodialysis		
	Regulation Number:	21 CFR 876.5820		
	Regulation Description:	Hemodialysis system and accessories		
	Device Class:	Class II		
	Classification Product Code:	KOC		
	Regulation Medical Specialty:	Gastroenterology/Urology		
		Gastroenterology/Urology		
Technological	The subject device and predicate	e device have substantially equivalent technological characteristics:		
Characteristics	Similar intended use includ	ling similar indication for use.		
	• Similar design and configu	ration.		
	Same scientific technology	and principles of operation.		
	The following are the only minor differences:			
	 EOG sterilization is adopted as the sterilization method. 			
		ermoplastic elastomer (SEBS), Isoprene rubber (IR) and Methyl		
	Methacrylate Acrylonitrile Butadiene Styrene (MABS) as new materials.			
		In addition to traditional transducer protection filters, PODs (Pressure monitor pod) are used		
		as a connection component to the pressure measurement unit.		
	• Compliance with the latest	•		
FDA Guidance		ocuments were referenced in preparing this premarket notification:		
Documents	 eCopy Program for Medical Device Submissions, issued April 2020 			
		Abbreviated 510(k)s, issued September 2019		
		ogen and Endotoxins Testing: Questions and Answers, issued June		
	2012			
	Hemodialysis Blood Tubing	g Sets, issued April 2008		
	 Labeling: Regulatory Requirements for Medical Devices, issued August 1989 			
	 Recommended Content and Format of Non-Clinical Bench Performance Testing Inform in Premarket Submissions, issued December 2019 			
	 Shelf Life of Medical Devices, issued April 1991 			
		of Sterility Information in Premarket Notification (510(k))		
	Submissions for Devices Labeled as Sterile, issued January 2016			
		ard ISO 10993-1, "Biological evaluation of medical devices - Part		
	1: Evaluation and testing w	within a risk management process", issued June 2016		

K230514 Page 3 of 4

Performance - Bench	Bench testing was completed to confirm that the subject device is substantially equivalent in performance.				
	A summary of the performance tests is included in Appendix 23 Evaluation of EOG Sterile AL and C18 series for DBB-06.				
	The following 20 performance tests were performed.				
	No.	Test Item	Report		
	1	Sterilization Barrier System Performance Test	TR-20210412-070442-16 (Appendix 24)		
	2	Blood Pathway Flow Dynamics	TR-20210331-070442-01 (Appendix 25)		
	3	Colour Coding	VER-P301201-160 (Appendix 26)		
	4	Connectors to Haemodialyser	TR-20210412-070442-02 (Appendix 27)		
	5	Connectors to Ancillary Components	TR-20210412-070442-15 (Appendix 28)		
	6	Connectors to Vascular Access Device	TR-20210412-070442-03 (Appendix 29)		
	7	Mechanical Hemolysis	TR-20210412-070442-11 (Appendix 30)		
	8	Needle Access Ports	TR-20210412-070442-04 (Appendix 31)		
	9	Needleless Access Ports	TR-20210412-070442-05 (Appendix 32)		
	10	Blood Pathway Volume	TR-20210412-070442-06 (Appendix 33)		
	11	Structural Integrity	TR-20210412-070442-01 (Appendix 34)		
	12	Tensile Strength	TR-20210412-070442-13 (Appendix 35)		
	13	Transducer Protectors	TR-20210412-070442-10 (Appendix 36)		
	14	Dimensional and Workmanship Analysis	TR-20211101-070442-01 (Appendix 37)		
	15	Peak Pressure Test of EOG Sterile AL Series for DBB-06	TR-20230104-070442-01 (Appendix 38)		
	16	Pump Segment Performance	TR-20221222-070442-01 (Appendix 39)]	
	17	Air-capture Chamber Fill Level	TR-20220707-210531-03 (Appendix 40)]	
	18	Resist Kinking After Repeated Clamping	TR-20220707-210531-02 (Appendix 41)		
	19	Tubing Compliance	TR-20220707-210531-01 (Appendix 42)		
	20	Simulated Treatment	TR-20230523-070442-01 (Appendix 43)		

Performance- Animal	No animal performance data is submitted in this Traditional 510(k).	
Performance- Clinical	No clinical performance data is submitted in this Traditional 510(k).	
Substantial	The subject devices are substantially equivalent to the predicate device when evaluating intended	
Equivalence	use and technological characteristics.	
	• The subject devices have the same intended use as the predicate device.	
	• The subject devices and predicate device are substantially equivalent with only minor technological differences.	
	• These differences do not raise new questions of safety and effectiveness.	
Conclusion	This comparison demonstrates that the subject devices are substantially equivalent to the predicate	
	device. The subject devices are as safe and effective as the predicate device and will perform as	
	intended.	